You Won't Believe What Cannabis Is Treating Now

Please do not reply to this message, as replies are routed to an unmonitored mailbox. You are receiving this email as a part of your subscription to Cannabis Profits Daily. If you have any questions or would like to change free your email settings, please reference the contact information at the bottom of this email. [Cannabis Profits Daily] Monday, February 25, 2019 [A New Condition for Medical Cannabis Treatment]( By Greg Miller By now, you're familiar with the [incredible potential of cannabis-based medicine](. And as a founding member of the National Institute for Cannabis Investors, you've heard me talk about Epidiolex. Late last year, Epidiolex, an epilepsy treatment developed by GW Pharmaceuticals (Nasdaq: [GWPH](), gained its status as the first-ever cannabis-based drug to achieve [FDA approval](. Epidiolex is currently only available for prescription to patients suffering from Dravet Syndrome and Lennox-Gastaut Syndrome, which are not very common. Because these forms of epilepsy did not respond to other treatments, GW Pharmaceuticals was able to gain "orphan drug" status, lowering the company's costs and providing a window in which other drugs are not allowed to compete. I'm glad this can help folks, but there's much more cannabis-based medicine can do. It has the potential to treat much more than just epilepsy. Thankfully, some states realize this and are allowing those affected with various medical conditions to access cannabis. Depending on where you live, you may be able to obtain a medical cannabis card for conditions like: - Alzheimer's - Glaucoma - Multiple sclerosis - Crohn's Disease - Anorexia - PTSD - Muscle spasms - Nausea - Chronic pain And that's by no means an exhaustive list of conditions it could treat. Keep in mind that studying cannabis has not been easy because of its status as a Schedule 1 drug in the United States. However, Israel has been a research powerhouse, and the country's top scientists have found interesting results when it comes to cannabis and autism. This could be a blessing for parents and their families, and it's one of those situations where people can be helped and you can make money. [In fact, from what they uncovered in this study, cannabis could completely change the way we treat autism spectrum disorders...]( [Uncover the Hottest IPOs Set to Hit the Market in 2019]( [Cannabis Is Gearing Up for a Seismic Shift - Are You Ready?]( [The Best Stock Screener Every Cannabis Investor Should Be Using]( How to Become the Ultimate Pot IPO Insider We're about to see an explosion of new cannabis IPOs hit the market. And for smart investors who get in on IPO day, the gains can be incredible. We're talking about the potential for each of these stocks to soar [200%, 500%, 1,000%, or more, practically overnight](. Just [click here]( to find out more. Over the years, the team here at the Institute has noticed a trend. If you want to beat Wall Street, if you want to trade like America's elite, you need to have [this one invaluable tool in your arsenal.]( Not only does it help you cut through the market noise, it [also helps pinpoint the most lucrative profit opportunities in the game](. And if you [click the link below](, we can show you how you can get this powerful investing tool at your fingertips. --------------------------------------------------------------- You are receiving this e-mail at {EMAIL}, as a part of your subscription. Remove your email from this list: [Unsubscribe]( © 2019 The National Institute for Cannabis Investors All Rights Reserved The National Institute for Cannabis Investors | 1125 N Charles Street | Baltimore, MD 21201 Toll Free: 866.260.0361; International: 410.777.8270 [Contact Customer Service](mailto:support@nicinvestors.com?subject=Cannabis%20Profits%20Daily%20Question) Website: []( Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This information may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The National Institute for Cannabis Investors, 1125 N Charles Street, Baltimore, MD 21201. [Privacy Policy]( | [Terms & Conditions](